Oncology Medical News about human genome

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Every microsatellite is different: Intrinsic DNA features dictate mutagenesis of common microsatellites present in the human genome
Molecular Carcinogenesis, 04/01/09

Eckert KA et al. - Inhibition of DNA synthesis within common microsatellites is highly sequence-dependent, and is positively correlated with the production of errors. DNA secondary structure within common microsatellites can account for some DNA polymerase pause sites, and may be an important factor influencing mutational specificity.

<< Previous
Peptide nucleic acid (PNA) binding and its effect on in vitro...

Next >>
Selection for the G4 DNA motif at the 5[prime] end of human genes

Human genome sciences invites investors to listen to webcast of presentation at jmp securities conference
Human Genome Sciences, 10/02/09 Relevance Score: 68%

GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus
GlaxoSmithKline, 11/03/09 Relevance Score: 66%

Human genome sciences announces third quarter 2009 financial results and key developments
Human Genome Sciences, 10/30/09 Relevance Score: 66%

GlaxoSmithKline and Human Genome Sciences announce full presentation at ACR of positive phase 3 study results for BENLYSTA in systemic lupus erythematosus
GlaxoSmithKline, 10/21/09 Relevance Score: 66%

Human genome sciences to host november 2nd conference call to discuss top-line results from second phase 3 trial of benlysta (belimumab) in systemic lupus erythematosus
Human Genome Sciences, 10/16/09 Relevance Score: 66%